Emergent Biosolutions Net Income

Emergent Biosolutions (EBS) currently reports a net income of $-180M as of June 2026. That compares with $140M in the prior-year period — down 231.6% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Emergent Biosolutions's net income history and peer comparisons.

Emergent Biosolutions's net income decreased from $140M to $-180M — a 231.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Emergent Biosolutions's net income of $-180M is lower than the Healthcare sector average of $16B. That is roughly 101.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Emergent Biosolutions reported $-180M in net income as of June 2026. That compares with $140M in the prior-year period — down 231.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-180M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Emergent Biosolutions, and consider following EBS for alerts when major investors trade the stock.